IL1B and infection: As this mechanism, or mechanisms, is still unresolved, global blockade of IL-1β, independent of specific inflammasomes, remains the preferred treatment modality for inflammasomopathies despite patient susceptibility to life-threatening infections (67, 69, 71–73).